Mangalam Drugs & Organics Limited

NSE MANGALAM.NS

Mangalam Drugs & Organics Limited Gross Profit Margin for the year ending March 31, 2024: 5.12%

Mangalam Drugs & Organics Limited Gross Profit Margin is 5.12% for the year ending March 31, 2024, a -84.14% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Mangalam Drugs & Organics Limited Gross Profit Margin for the year ending March 31, 2023 was 32.29%, a 6.10% change year over year.
Mangalam Drugs & Organics Limited Gross Profit Margin for the year ending March 31, 2022 was 30.44%, a -6.80% change year over year.
Mangalam Drugs & Organics Limited Gross Profit Margin for the year ending March 31, 2021 was 32.66%, a 10.01% change year over year.
Mangalam Drugs & Organics Limited Gross Profit Margin for the year ending March 31, 2020 was 29.69%, a -3.26% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NSE: MANGALAM.NS

Mangalam Drugs & Organics Limited

CEO	Mr. Govardhan Murlidhar Dhoot
IPO Date	May 23, 2005
Location	India
Headquarters	Rupam Building
Employees	432
Sector	Health Care
Industries Pharmaceuticals Chemicals & Advanced Materials

Description

Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for use in anti-malarial, analgesic/anti-inflammatory, anti-hypertensive, and anti-retroviral applications. The company was incorporated in 1972 and is based in Mumbai, India.

Key trends

Past 5 years